• Je něco špatně v tomto záznamu ?

Implementing reversed-phase and hydrophilic interaction liquid chromatography into the characterization of DTPA-ramucirumab conjugate before radiolabeling

DK. Naplekov, P. Bárta, F. Trejtnar, H. Sklenářová, J. Lenčo

. 2023 ; 235 (-) : 115615. [pub] 20230731

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016074

Radioimmunoconjugates represent a promising class of therapeutics and diagnostics. The characterization of intermediate chelator-antibody products, i.e., without the radionuclide, is frequently omitted, bringing significant uncertainty in the radioimmunoconjugate preparation. In the present study, we explored the utility of reversed-phase (RPLC) and hydrophilic interaction (HILIC) liquid chromatography with UV detection to characterize ramucirumab stochastically conjugated with p-SCN-Bn-CHX-A"-DTPA chelator (shortly DTPA). The conjugation was well reflected in RPLC chromatograms, while chromatograms from HILIC were significantly less informative. RPLC analyses at the intact level confirmed that the conjugation resulted in a heterogeneous mixture of modified ramucirumab. Moreover, the RPLC of DTPA-ramucirumab confirmed heterogeneous conjugation of all subunits. The peptide mapping did not reveal substantial changes after the conjugation, indicating that most parts of ramucirumab molecules remained unmodified and that the DTPA chelator was bound to various sites. Eventually, the RPLC method for analysis of intact ramucirumab was successfully applied to online monitoring of conjugation reaction in 1 h intervals for a total of 24 h synthesis, which readily reflected the structural changes of ramucirumab in the form of retention time shift by 0.21 min and increase in peak width by 0.22 min. The results were obtained in real-time, practically under 10 min per monitoring cycle. To the best of our knowledge, our study represents the first evaluation of RPLC and HILIC to assess the quality of intermediates during the on-site preparation of radioimmunoconjugates prior to radiolabeling.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016074
003      
CZ-PrNML
005      
20231026110501.0
007      
ta
008      
231013s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jpba.2023.115615 $2 doi
035    __
$a (PubMed)37566949
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Naplekov, Denis K $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Analytical Chemistry, Akademika Heyrovskeho 1203/8, 500 05 Hradec Kralove, Czech Republic
245    10
$a Implementing reversed-phase and hydrophilic interaction liquid chromatography into the characterization of DTPA-ramucirumab conjugate before radiolabeling / $c DK. Naplekov, P. Bárta, F. Trejtnar, H. Sklenářová, J. Lenčo
520    9_
$a Radioimmunoconjugates represent a promising class of therapeutics and diagnostics. The characterization of intermediate chelator-antibody products, i.e., without the radionuclide, is frequently omitted, bringing significant uncertainty in the radioimmunoconjugate preparation. In the present study, we explored the utility of reversed-phase (RPLC) and hydrophilic interaction (HILIC) liquid chromatography with UV detection to characterize ramucirumab stochastically conjugated with p-SCN-Bn-CHX-A"-DTPA chelator (shortly DTPA). The conjugation was well reflected in RPLC chromatograms, while chromatograms from HILIC were significantly less informative. RPLC analyses at the intact level confirmed that the conjugation resulted in a heterogeneous mixture of modified ramucirumab. Moreover, the RPLC of DTPA-ramucirumab confirmed heterogeneous conjugation of all subunits. The peptide mapping did not reveal substantial changes after the conjugation, indicating that most parts of ramucirumab molecules remained unmodified and that the DTPA chelator was bound to various sites. Eventually, the RPLC method for analysis of intact ramucirumab was successfully applied to online monitoring of conjugation reaction in 1 h intervals for a total of 24 h synthesis, which readily reflected the structural changes of ramucirumab in the form of retention time shift by 0.21 min and increase in peak width by 0.22 min. The results were obtained in real-time, practically under 10 min per monitoring cycle. To the best of our knowledge, our study represents the first evaluation of RPLC and HILIC to assess the quality of intermediates during the on-site preparation of radioimmunoconjugates prior to radiolabeling.
650    12
$a chromatografie s reverzní fází $x metody $7 D056148
650    _2
$a chromatografie kapalinová $x metody $7 D002853
650    _2
$a hydrofobní a hydrofilní interakce $7 D057927
650    12
$a imunokonjugáty $7 D018796
650    _2
$a chelátory $7 D002614
650    _2
$a kyselina pentetová $7 D004369
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bárta, Pavel $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Biophysics and Physical Chemistry, Akademika Heyrovskeho 1203/8, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Trejtnar, František $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Akademika Heyrovskeho 1203/8, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Sklenářová, Hana $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Analytical Chemistry, Akademika Heyrovskeho 1203/8, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Lenčo, Juraj $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Analytical Chemistry, Akademika Heyrovskeho 1203/8, 500 05 Hradec Kralove, Czech Republic. Electronic address: lenco@faf.cuni.cz
773    0_
$w MED00002894 $t Journal of pharmaceutical and biomedical analysis $x 1873-264X $g Roč. 235, č. - (2023), s. 115615
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37566949 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026110455 $b ABA008
999    __
$a ok $b bmc $g 1999915 $s 1202436
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 235 $c - $d 115615 $e 20230731 $i 1873-264X $m Journal of pharmaceutical and biomedical analysis $n J Pharm Biomed Anal $x MED00002894
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...